Business Wire

LevelBlue and Akamai Partner to Launch New Managed Web Application and API Protection Services

Share

Tiered offerings offer flexible web application and API protection, helping organizations consolidate, simplify, and scale security

LevelBlue, a leading provider of managed security services, strategic consulting, and threat intelligence, today announced the launch of its Managed Web Application and API Protection (WAAP) security service, designed to deliver adaptive, always-on protection that can reduce risk and operational overhead for web application and API security. Powered by Akamai’s industry-leading App & API Protector technology, LevelBlue Managed WAAP combines next-gen web application firewall (WAF), distributed-denial-of service (DDoS) mitigation, bot protection, and foundational API security capabilities paired with LevelBlue’s dedicated WAAP Operations team.

Organizations globally are rapidly scaling their use of applications and APIs to power digital-first strategies. According to Enterprise Strategy Group, the average number of web applications per organization is expected to grow from 145 to more than 200 within two years. Simultaneously, the number of organizations with more than half of their applications using APIs will rise from 32% to 80%. Among the most critical challenges security teams face are:

  • Discovering application and API deployments
  • Scaling adequate protections
  • Swiftly identifying and mitigating attacks
  • Ensuring security does not impact performance

In addition, many struggle with staff constraints and an expertise gap. As environments grow more complex, half of midmarket organizations say it's harder to secure web apps and APIs than it was just two years ago, and so many are seeking external help and simplified, consolidated solutions. LevelBlue Managed WAAP directly addresses these needs, delivering measurable security outcomes while streamlining operations.

“Today, a surprising number of organizations rely on multiple tools that are not purpose-built for web application and API security—leading to complexity, silos, and rising costs,” said Sundhar Annamalai, president of LevelBlue. “LevelBlue offers an alternative: proven services that consolidate and simplify protections with predictable investment. By combining LevelBlue’s operational expertise with Akamai’s proven technology, organizations can stay ahead of evolving threats and create cyber resilience for critical digital capabilities.”

LevelBlue Managed WAAP is available in two tiers, Essential and Advanced, giving organizations the flexibility to choose a service level that best meets their needs. Core benefits include:

  • Access 24/7 WAAP expertise: Gain a fully operational team of specialists delivering around-the-clock support, monitoring, and advisory to improve WAAP protection.
  • Discover and secure critical assets: Automatically identify and classify web apps and APIs—prioritize those exposed or handling sensitive data, and scale protection as needed.
  • AI-Powered Threat Defense: Combine AI-driven detection with global threat intelligence to spot anomalies, adapt to new attack vectors, and stay ahead of threats.
  • Streamlined Security Management: Eliminate manual tuning with expert-led, automated policy management, boosting efficiency, reducing false positives, and aligning with modern DevOps workflows.

“In 2024 alone, Akamai saw over 311 billion web app attacks. As AI accelerates, threats are harder to spot, and security is tougher to control,” said Rupesh Chokshi, Senior Vice President and General Manager of Akamai’s Application Security Portfolio. “Akamai and LevelBlue’s partnership gives customers access to a trusted, reliable team that combines industry-leading technology with the deep operational expertise of one of the world’s largest MSSPs. It’s a powerful combination with a flexible solution that can fast-track organizations to resilient protection and compliance."

To learn more about LevelBlue Managed WAAP services, please visit here.

About LevelBlue
We simplify cybersecurity through award-winning managed services, experienced strategic consulting, threat intelligence, and renowned research. Our team is a seamless extension of yours, providing transparency and visibility into security posture and continuously working to strengthen it.

We harness security data from numerous sources and enrich it with artificial intelligence to deliver real-time threat intelligence- this enables more accurate and precise decision making. With a large, always-on global presence, LevelBlue sets the standard for cybersecurity today and tomorrow. We easily and effectively manage risk, so you can focus on your business.

Welcome to LevelBlue. Cybersecurity. Simplified. Learn more at www.levelblue.com.

About Akamai
Akamai is the cybersecurity and cloud computing company that powers and protects business online. Our market-leading security solutions, superior threat intelligence, and global operations team provide defense in depth to safeguard enterprise data and applications everywhere. Akamai’s full-stack cloud computing solutions deliver performance and affordability on the world’s most distributed platform. Global enterprises trust Akamai to provide the industry-leading reliability, scale, and expertise they need to grow their business with confidence. Learn more at akamai.com and akamai.com/blog, or follow Akamai Technologies on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250812788980/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release

Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t

Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a

Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release

Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye